In Brief: Novartis' Transderm Scop
This article was originally published in The Tan Sheet
Executive Summary
Novartis' Transderm Scop: Rx scopolamine motion sickness transdermal patch being reintroduced through direct-mail campaigns to health care professionals in September and consumers in November. Transderm Scop originally was marketed as an OTC product. In an attempt to position Transderm Scop against available OTC motion sickness alternatives such as Pharmacia & Upjohn's Dramamine, Novartis is relying on lower pricing and insurance coverage of the Rx product. The scopolamine 1.5 mg patch will begin shipping Oct. 1 and reach pharmacy shelves in mid-November. The product was withdrawn from the market in August 1994 due to manufacturing problems. Novartis received FDA approval to modify the manufacturing process in October. The brand is being remarketed under the company's Consumer Health division...